Supraventricular tachyarrhythmia in patients with Brugada syndrome: A single-center study  by Ohkubo, Kimie et al.
Journal of Arrhythmia 29 (2013) 265–269Contents lists available at ScienceDirectJournal of Arrhythmia1880-42
http://d
n Corr
Univers
173-861
E-mjournal homepage: www.elsevier.com/locate/joaOriginal ArticleSupraventricular tachyarrhythmia in patients with Brugada syndrome:
A single-center study
Kimie Ohkubo a, Ichiro Watanabe a,n, Yasuo Okumura a, Masayoshi Kofune a,
Koichi Nagashima a, Hiroaki Mano a, Kazumasa Sonoda a, Toshiko Nakai a, Satoshi Kunimoto a,
Yuji Kasamaki a, Atsushi Hirayama a, Naokata Sumitomob, Tomohiro Nakayama c
a Division of Cardiology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan
b Department of Pediatrics, Nihon University School of Medicine, Tokyo, Japan
c Department of Laboratory Medicine, Nihon University School of Medicine, Tokyo, Japana r t i c l e i n f o
Article history:
Received 31 October 2012
Received in revised form
9 January 2013
Accepted 25 January 2013
Available online 29 April 2013
Keywords:
Brugada syndrome
Supraventricular tachycardia
Atrial ﬁbrillation76/$ - see front matter & 2013 Japanese Hear
x.doi.org/10.1016/j.joa.2013.01.014
espondence to: Division of Cardiology, Dep
ity School of Medicine, 30-1 Oyaguchi-Kam
0, Japan. Tel.: +81 3 3972 8111x2412; fax: +81
ail address: watanabe.ichirou@nihon-u.ac.jp (a b s t r a c t
Background: Brugada syndrome is a distinct form of idiopathic ventricular ﬁbrillation. We retrospectively
investigated the incidence and clinical implications of supraventricular tachyarrhythmia in patients with
Brugada syndrome.
Methods: We reviewed 69 consecutive cases of Brugada syndrome, 11 of which had a history of syncope.
Results: Seven patients (10.1%) had clinically documented supraventricular tachyarrhythmia: 3 patients
with atrioventricular reentrant tachycardia, 2 with atrioventricular nodal reentrant tachycardia, and
2 with paroxysmal atrial ﬁbrillation. The prevalence of a spontaneous type 1 Brugada electrocardiogram
and symptoms (history of syncope, presyncope, documented ventricular tachyarrhythmia, or aborted
sudden cardiac death) were signiﬁcantly higher, and QRS duration was signiﬁcantly longer in patients
without than in those with supraventricular tachyarrhythmia. The PR and AH intervals were also longer
in patients without than in those with supraventricular tachyarrhythmia, but the differences were not
statistically signiﬁcant.
Conclusion: The arrhythmogenic substrate in Brugada syndrome may not be restricted to the ventricles.
Palpitations in patients with this syndrome should raise the question of supraventricular tachyarrhythmia.
Conversely, in patients with supraventricular tachyarrhythmia and aborted sudden cardiac death or syncope
not related to supraventricular tachyarrhythmia, Brugada syndrome should be considered a possible
additional electrophysiologic abnormality.
& 2013 Japanese Heart Rhythm Society. Published by Elsevier B.V. All rights reserved.1. Introduction
Brugada syndrome is characterized by ST elevation in the right
precordial leads on electrocardiogram (ECG) and poses a high risk
of sudden cardiac death (SCD), for which the mean age is
approximately 40 yr [1]. Brugada syndrome is thought to account
for 4–12% of all cardiac deaths and at least 20% of deaths in
patients with a structurally normal heart [2]. The syndrome
follows an autosomal dominant mode of transmission with
incomplete penetrance. Mutations in the SCN5A gene encoding
the cardiac sodium channel and other types of ion channels (ICaL,
IKs, and Ito) have been reported as the genetic basis of the disease
[3–8]. Because these ion channels are not restricted to ventriculart Rhythm Society. Published by Els
artment of Medicine, Nihon
imachi, Itabashi-ku, Tokyo
3 3972 1098.
I. Watanabe).tissue, the electrical abnormality might also affect the atria, and
indeed, an association between supraventricular tachyarrhythmias
and Brugada syndrome has been reported [9–11]. However, the
incidence and clinical consequences of supraventricular tachyar-
rhythmia in patients with Brugada syndrome have not been
clariﬁed. Therefore, in a retrospective, single-center, follow-up
study, we assessed the incidence and clinical implications of
supraventricular tachyarrhythmia in patients with Brugada
syndrome.2. Methods
2.1. Patients
Sixty-nine consecutive patients with a spontaneous or drug-
induced (pilsicainide, 1 mg/kg, given intravenously) Brugada type
1 ECG examined at the Nihon University Hospital between 1996
and 2011, were selected for this study. The ECG diagnosis ofevier B.V. All rights reserved.
Table 1
Clinical, genetic, electrocardiographic, and electrophysiologic characteristics of
study patients (n¼69).
Age (y) 49.9713.4
Sex ratio (M/F) 66/3
Symptomatic 11
Family history of SCD 5
Spontaneous Brugada type 1 ECG pattern 47
SCN5A gene mutation 2
Late potential 35/60 (58.3%)
PR interval in lead II (ms) 170.4722.2
QTc in lead II (ms) 413.7723.5
QRS duration in lead II (ms) 105.0716.5
EPS 53
AH interval (ms) 101.4719.6
HV interval (ms) 49.5712.2
Inducible VF/PVT at EPS 45
ICD implantation 18
Follow-up (mo) 84.0750.9
Arrhythmic event during follow-up 1
Data are number of patients unless otherwise indicated.
SCD, sudden cardiac death; BS, Brugada syndrome; EPS, electrophysiologic study;
VF, ventricular ﬁbrillation; PVT, polymorphic ventricular tachycardia; ICD, implan-
table cardioverter deﬁbrillator.
Table 2
Clinical, genetic, electrocardiographic, and electrophysiologic characteristics of
study patients with and without supraventricular tachycardia.
Patients with SVT
(n¼7)
Patients without SVT
(n¼62)
P value
Age (y) 56.0716.0 49.2713.1 0.18
Sex ratio (M/F) 7/0 59/3 0.26
Symptomatic 0 11 o0.001
Family history of SCD 1 4 0.45
Spontaneous type 1 ECG
pattern
2 45 0.018
Late potential 4/5 31/55 0.30
SCN5A gene mutation 0 2 0.63
PR interval (ms) 156.9717.5 171.8722.3 0.13
QTc (ms) 412.3721.3 413.8723.8 0.81
QRS duration (ms) 95.7723.5 105.9715.5 0.044
EPS 6 47 0.56
AH interval (ms) 85.8712.3 103.2719.5 0.033
HV interval (ms) 49.579.4 49.4712.6 0.78
Inducible VF/PVT at EPS 4/6 41/47 0.19
ICD implantation 0 18 0.097
Follow-up (mo) 84.0.748.2 84.0751.5 0.91
Arrhythmic event during
follow-up
0 1 0.74
Data are number of patients unless otherwise indicated.
SVT, supraventricular tachycardia; SCD, sudden cardiac death; BS, Brugada syn-
drome; EPS, electrophysiologic study; VF, ventricular ﬁbrillation; PVT, polymorphic
ventricular tachycardia; ICD, implantable cardioverter deﬁbrillator.
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second consensus conference, held in 2003 [2]. No patient with a
true right bundle branch block was included. All patients had
undergone transthoracic echocardiography, and 53 of the 69
patients had undergone cardiac catheterization, coronary angio-
graphy, left and right ventricular angiography, and electrophysio-
logic study. Laboratory tests had been performed at our outpatient
clinic to exclude electrolyte and metabolic disturbances. The
following clinical data were obtained from the patients' admission
records: age, sex, symptom(s) vs. no symptom(s), family history vs.
no family history of SCD (o45 yr of age), ECG pattern (type 1, type
2, or type 3 before the drug challenge test), and treatment vs. no
treatment with an implantable cardioverter deﬁbrillator (ICD).
Patients with a history of syncope, presyncope, documented
ventricular tachyarrhythmia, or aborted SCD were considered
symptomatic. Patients with established neurally mediated syn-
cope were considered asymptomatic. Screening for SCN5A gene
mutations had been performed in 39 of the patients according to
the Nihon University School of Medicine and Nihon University
Hospital guidelines for genetic research.
2.2. Signal-averaged electrocardiography
A ventricular signal-averaged ECG (ART 1200EPX signal-
averaged ECG system; Arrhythmia Research Technology Inc.,
Austin, TX, USA; noise level o0.3 μV and bidirectional high-pass
ﬁltering [40 Hz] with a bidirectional 4-pole Butterworth ﬁlter) had
been recorded in 60 patients. At our institution, a positive late
potential was deﬁned as a root mean square voltage of the last
40 ms of o20 μV [12].
2.3. Coronary angiography, left ventriculography, and
electrophysiologic study
Coronary angiography, left ventriculography, and comprehen-
sive electrophysiologic study had been performed in 53 of the 69
patients in a fasting, drug-free, nonsedated state. After access to
the right femoral vein was gained at 2 sites, left femoral vein at
1 site, right internal jugular vein at 1 site, and right femoral artery
at 1 site, coronary arteriography and left ventriculography were
performed. In patients in whom supraventricular tachycardia was
induced, the mechanism of the tachycardia was examined and
radiofrequency catheter ablation was performed. In patients with
paroxysmal atrial ﬁbrillation (AF), extensive encircling circumfer-
ential pulmonary vein isolation was performed. Two steerable
quadripolar catheters (6F) with an interelectrode distance of 2–5–
2 mm (Biosense-Webster, Diamond Bar, CA, USA) were then
positioned in the right atrial appendage and right ventricular
apex, respectively. An octapolar catheter with an interelectrode
distance of 2–2–2 mm (BARD Electrophysiology, Lowell, MA, USA)
was positioned at the His bundle electrogram recording position,
and a decapolar catheter with an interelectrode distance of 2–5–
2 mm (DAIG/St. Jude Medical Inc., Minneapolis, MN, USA) was
placed in the coronary sinus. Endocardial potentials were ﬁltered
to recording frequencies of 30–500 Hz and recorded on a BARD
computer system (BARD Lab Pro, BARD Electrophysiology). Pro-
grammed electrical stimulation from the right ventricular apex
and right ventricular outﬂow tract was performed at 2 times
diastolic threshold strength and pulse width of 2 ms with a pulse
generator (BD-02; Fukuda Denshi Co., Tokyo, Japan). An S1–S2
interval was applied after 8 beats of drive pacing (S1) at basic cycle
lengths of 600 and 400 ms from the right atrial appendage. The
S1–S2 interval was decreased in 10-ms steps until the effective
refractory period of the right atrium was reached. When sustained
supraventricular tachyarrhythmia was not induced with a single
premature beat, 2 extrastimuli (S2 and S3 until the effectiverefractory period) were delivered. An S1–S2 interval was also
applied after 8 beats of drive pacing (S1) at basic cycle lengths of
600 and 400 ms from the right ventricular apex, and outﬂow tract.
The S1–S2 interval was decreased in 10-ms steps until the effective
refractory period of the right ventricle was reached. When poly-
morphic ventricular tachycardia or ventricular ﬁbrillation (VF)
lasting more than 5 s requiring direct current shock was not
induced with a single premature beat, 3 extrastimuli (S2 until
the effective refractory period was reached, S3, and S4 to 180 ms)
were delivered.2.4. Follow-up
In general, patients had been followed up at 4- to 5-month
intervals at our outpatient clinic to determine the status of their
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84.0750.9 months; median 91 months)2.5. Statistical analysis
Continuous clinical and electrophysiologic values are shown as
mean7SD. In this study, patients were divided according to the
presence or absence of supraventricular tachyarrhythmia. Differ-
ences in continuous clinical variables were analyzed by the Mann-
Whitney U test, and associations between categorical variables
were analyzed by the Fisher's exact probability test. A P value of
o0.05 was considered statistically signiﬁcant. StatView 5.0 (SAS
Institute, Cary, NC, USA) was used for analysis.3. Results
The study group comprised 66 men and 3 women with a mean
age of 50.7713.6 yr (range, 24–76 yr). Forty-seven patients had
spontaneous Brugada type 1 ECG, and 22 had drug-induced
Brugada type 1 ECG (conversion from type 2 [n¼12] or type 3
[n¼10]). The clinical, genetic, electrocardiographic, and electro-
physiologic characteristics of the study patients are shown in
Tables 1 and 2. Eleven patients were symptomatic (syncope,
n¼3; presyncope, n¼2; aborted SCD, n¼6; mean age,
52.5714.2 yr [range, 25–76 yr]), and 57 patients were asympto-
matic (mean age, 50.3713.5 yr [range, 24–75 yr]). Five patients
had a family history of SCD. An SCN5A gene mutation was found in
2 patients (5.1%). Supraventricular tachyarrhythmias were found in
7 patients (supraventricular tachycardia, 2 patients; paroxysmal
AF, 2 patients) (10.1%). The prevalence of a spontaneous type
1 Brugada ECG and symptoms (history of syncope, presyncope,
documented ventricular tachyarrhythmia, or aborted SCD) were
signiﬁcantly higher, and QRS duration was signiﬁcantly longer, in
patients without supraventricular tachyarrhythmia than in those
with supraventricular tachyarrhythmia. The PR and AH intervals
were longer in patients without than in those with supraventri-
cular tachyarrhythmia; however, the differences were not statisti-
cally signiﬁcant (Table 2).3.1. Coronary angiography and left ventriculography
Of the 69 patients, 53 underwent coronary angiography and
ventriculography, the left ventricular ejection fraction was 69.2%
78.8% (range, 46–89%). The coronary angiograms of 49 patients
were normal, whereas signiﬁcant coronary artery disease was
present in the remaining 4 patients who had undergone pertinent
studies.Table 3
Clinical characteristics of Brugada syndrome patients with supraventricular
tachyarrhythmia.
Patient Age (y) Sex ECG FH LP VF induction (ms) SVT
1 29 Male 2 – + A:600/230/210 AVRT
2 63 Male 1 – + O:400/210/180 AVNRT
3 61 Male 2 – + O:400/270/270/200 AVRT
4 41 Male 3 – – O:400/200/200/190 PAF
5 68 Male 3 – NA Not induced AVNRT
6 75 Male 3 – NA A:600/220/200 PAF
7 55 Male 3 – + NA AVRT
ECG, Brugada type ECG pattern; FH, family history of sudden cardiac death; LP, late
potential; VF, ventricular ﬁbrillation; A, right ventricular apex; O, right ventricular
outﬂow tract; NA, data not available; AVRT, atrioventricular reentrant tachycardia;
AVNRT, atrioventricular nodal reentrant tachycardia; PAF, paroxysmal atrial
ﬁbrillation.3.2. Electrophysiologic study
In patients in whom supraventricular tachycardia was induced
with programed atrial stimulation, the mechanism of the tachy-
cardia was examined. Atrioventricular reentrant tachycardia was
induced in 3 of the 7 patients with supraventricular tachyarrhyth-
mia, atrioventricular nodal reentrant tachycardia (AVNRT) was
induced in 2 patients, and AF was induced in 2 patients. Radio-
frequency catheter ablation was performed for the accessory
atrioventricular pathway in the 3 patients with concealed Wolff-
Parkinson-White syndrome and the slow atrioventricular nodal
pathway in the 2 patients with AVNRT; circumferential pulmonary
vein isolation was performed in the 2 patients with paroxysmal AF
(Table 3).
Programmed ventricular stimulation induced VF/polymorphic
ventricular tachycardia in 45 patients (84.9%). An ICD had been
implanted in 18 of these patients (Table 2). There were no
differences in the electrophysiologic characteristics and inducibil-
ity of VF/polymorphic ventricular tachycardia between patients
with and without supraventricular tachycardia (Table 2).
3.3. Follow-up
No patient died during the follow-up period. One patient had
an arrhythmic event (VF) at 4 months after the electrophysiologic
study.4. Discussion
Supraventricular arrhythmias are being increasingly recognized
in patients with Brugada syndrome. Incidences of spontaneous
supraventricular tachyarrhythmia of between 6% and 39% have
been reported [13]. The reported inducibility of supraventricular
tachyarrhythmia ranges from 3% to 100% [13]. Bordachar et al. [10]
suggested that the disease process is more advanced in patients
with Brugada syndrome and supraventricular tachyarrhythmia.
Sacher et al. conducted one of the largest studies to yield data on
supraventricular tachyarrhythmias in patients with Brugada syn-
drome [14]. In this study, supraventricular tachyarrhythmias were
documented in 32 of their 220 patients, with 23 of the 32 (10% of
the total patients) having AF. AF is the most common atrial
arrhythmia found in Brugada syndrome, with a prevalence varying
between 10% and 39% (Table 4) [1,10,11,15–17], although a few
cases of associated AVNRT and atrioventricular reentrant tachy-
cardia with an accessory pathway have also been noted [9,18–21].
These data indicate that, in patients with supraventricular tachyar-
rhythmia, Brugada syndrome should be added to the list of
possible causes of syncope or aborted SCD, even in the presence
of an accessory pathway. In our patient series, the incidence of AF
(2 of 69 [2.9%]) was lower than the previously reported incidences
(Table 4); however, in the present study, AF was the ﬁrst clinical
manifestation before the diagnosis of manifest or latent BrugadaTable 4
Reported incidences of atrial ﬁbrillation/atrial ﬂutter associated with Brugada
syndrome.
Authors
Brugada and Brugada [1] 2/8 25%
Itoh et al. [15] 9/30 30%
Morita et al. [16] 7/18 39%
Bordachar et al. [10] 11/59 19%
Probst et al. [17] 3/30 10%
Schimpf et al. [11] 13/115 11%
Rodríguez-Mañero et al. [23] 35/611 5.7%
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patients) of new-onset AF as the ﬁrst clinical manifestation
showed spontaneous or drug-induced type 1 Brugada ECG pattern,
and Rodríguez-Mañero et al. [23] found that in 5.7% (35 of 611) of
patients, AF was diagnosed before the identiﬁcation of manifest or
latent Brugada syndrome. In the present study, AF was the ﬁrst
clinical manifestation, and type 1 Brugada ECG was unmasked by
the initiation of a class I antiarrhythmic drug. Therefore, our data
are similar to those of these 2 reports with regard to the number of
patients presenting with AF as the ﬁrst manifestation of latent
Brugada syndrome.
Among our study patients without supraventricular tachyar-
rhythmia, the prevalence of a spontaneous type 1 Brugada ECG
and symptoms were higher and QRS duration was longer than in
those with supraventricular tachyarrhythmia. Previous studies
have revealed a spontaneous type 1 Brugada ECG and prolonged
QRS duration in symptomatic Brugada syndrome patients [24,25].
In addition, the PR and AH intervals were longer in our study
patients without supraventricular tachyarrhythmia than in those
with supraventricular tachyarrhythmia; however, the differences
did not reach statistical signiﬁcance. Another group of investiga-
tors also reported more prevalent PR prolongation (≥0.22 s)
among symptomatic than among asymptomatic patients, but the
difference was not statistically signiﬁcant [26]. The higher pre-
valence of a spontaneous type 1 ECG and longer PR and AH
intervals among patients without supraventricular tachyarrhyth-
mia might be related to the higher prevalence of symptoms related
to ventricular tachyarrhythmia.
The mechanism underlying syncope or resuscitated cardiac
arrest in patients with supraventricular tachyarrhythmia is often
unknown. Resuscitation occurs mainly in cases of Wolff-
Parkinson-White syndrome with a short refractory period of the
accessory pathway [27,28]. In young patients with a history of
palpitations, syncope may be a benign symptom. An abnormal
vasomotor response to the hemodynamic stress of tachycardia has
been suggested as one mechanism responsible for syncope [29].
Activation of cardiac mechanoreceptors during tachycardia may
lead to the withdrawal of sympathetic tone, enhanced vagal tone,
and hypotension [30]. The presence of concealed or intermittent
forms of Brugada syndrome makes diagnosis of the disease even
more difﬁcult in these cases [30]. Thus, if syncope or cardiac arrest
cannot be explained by the supraventricular tachyarrhythmia or
the conduction properties of an accessory pathway, Brugada
syndrome should be considered an additional disorder. If there is
any doubt that the supraventricular tachyarrhythmia is responsi-
ble for the clinical event, patients should be given an antiarrhyth-
mic drug such as pilsicainide or ﬂecainide, which may provoke
typical ECG signs of Brugada syndrome [1].
Supraventricular tachyarrhythmia is an important cause of
inappropriate ICD shocks in patients with Brugada syndrome
[10,13,31]. Bordachar et al. [10] reported that the number of
inappropriate ICD interventions (occurring in 14% of patients)
exceeded the number of appropriate ICD interventions (occurring
in 10% of patients). Kharazi et al. [32] reported a similar ﬁnding,
i.e., 41% of patients had inappropriate shocks, whereas 17% had
appropriate shocks, and Sacher et al. [14] found inappropriate
shocks to be 2.5 times more common than appropriate shocks in a
large population of Brugada syndrome patients treated with ICD.
Dual-chamber ICDs are useful in preventing such inappropriate
shocks in patients with paroxysmal AF; however, the beneﬁt must
be weighed against the increased complication rate associated
with the atrial lead placement.
A less invasive and sometimes simpler option is the use of rate-
lowering drugs. Careful programming of single-chamber ICDs is
also recommended to avoid inappropriate shocks in those without
documented AF. Class I antiarrhythmic drugs are often used for thetreatment of paroxysmal AF. Matsumoto et al. [33] described a
patient with intermittent or concealed Brugada syndrome who
developed VF after the administration of pilsicainide for the
treatment of AF. Therefore, Brugada syndrome should be consid-
ered before the administration of class Ic antiarrhythmic drugs in
patients with AF.
4.1. Study limitations
The number of supraventricular tachyarrhythmias might have
been underestimated in our patients owing to the eventual
presence of asymptomatic episodes; we previously induced AF
by 1 or 2 atrial extrastimuli in 11 of 11 Brugada syndrome patients
with no history of AF [21]. In addition, because of the small
number of patients with AF (n¼2 of 69), and only 6 of the 69
patients had aborted SCD, the incidence of AF associated with
Brugada syndrome and its prognostic signiﬁcance could not be
concluded.5. Conclusion
Palpitations in patients with Brugada syndrome should raise
the question of supraventricular tachyarrhythmia. Conversely, in
patients with supraventricular tachyarrhythmia and aborted SCD
or syncope not related to the tachyarrhythmia, Brugada syndrome
should be considered a possible electrophysiologic abnormality.Conﬂict of interest
The authors have no conﬂicts of interest related to this study.
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